Neoadjuvant abemaciclib and giredestrant for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause (no period for at least 12 months, or your ovaries removed at least 2 weeks ago).
- Your breast tumor measures at least 1 cm on ultrasound and has not spread to other parts of the body.
- Your tumor tests positive for estrogen receptors (at least 10% of cells) and negative for HER2 protein.
- You have not had any prior treatment for breast cancer (surgery, chemotherapy, hormone therapy, or radiation).
- Your tumor has a Ki67 score of 10% or higher (a marker of how fast cancer cells are growing).
- You are healthy enough for daily activities (ECOG score 0 or 1) and have adequate blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new combination of two oral medications—imlunestrant (a hormone therapy) and abemaciclib (a drug that blocks cancer growth)—given before surgery. The goal is to see if these drugs can shrink the tumor, using your tumor's growth rate (Ki67) after two weeks of treatment to guide further therapy.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.